Table 2.
Progression-free survival in locally advanced rectal cancer
| HR1 | 95 % CI | p-value | ||
|---|---|---|---|---|
| ΔNACT | 0.994 | (0.990–0.999) | 0.01 | |
| Age | 0.953 | (0.914–0.993) | 0.02 | |
| TN stage | T2–3 | |||
| T4 | 2.71 | (1.17–6.27) | 0.02 | |
| N0–1 | ||||
| N2 | 1.22 | (0.449–3.30) | 0.70 | |
| Baseline CEA level | ≤ULN | |||
| >ULN | 1.85 | (0.799–4.29) | 0.15 | |
| ypTN | ypT0–2 | |||
| ypT3–4 | 6.10 | (2.22–16.7) | <0.001 | |
| ypN0 | ||||
| ypN1–2 | 2.84 | (1.20–6.70) | 0.02 | |
| TRG score | TRG1–2 | |||
| TRG3–5 | 3.00 | (1.27–7.08) | 0.01 | |
Adjusted hazard ratio (HR) with 95 % confidence interval (CI) was calculated by univariate Cox regression analysis for each of the indicated variables
ΔNACT paired serum sample measurements of carbonic anhydrase IX following neoadjuvant induction chemotherapy versus baseline, CEA carcinoembryonic antigen, ULN upper limit of normal, TRG tumour regression grade
1: HR less than 1 indicates that patients had higher probability of favourable progression-free survival